Montelukast Pensa (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Pensa, is a leukotriene receptor antagonist presented as a unknown strength/oral dosage form for oral use. It is used for maintenance therapy of asthma and for allergic rhinitis in adults and children.

GNH USA supplies Montelukast Pensa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast, a leukotriene receptor antagonist, is used to manage conditions mediated by cysteinyl leukotrienes.

- Asthma (maintenance therapy): reduces the frequency of asthma attacks and improves overall disease control. - Allergic rhinitis: alleviates nasal congestion, sneezing, itching and rhinorrhea associated with seasonal or perennial allergies. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity, allowing better exercise tolerance.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort or cramping. - Cough: transient dry cough. - Sore throat: mild irritation of the throat. - Nausea: occasional upset stomach. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat. - Stevens‑Johnson syndrome: severe skin rash with blistering. - Anaphylaxis: rapid onset of life‑threatening allergic reaction. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic injury: abnormal liver function tests. - Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder.

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Hepatic function: use with caution in patients with liver impairment. - Hypersensitivity: avoid in individuals with known allergy to montelukast or any excipients. - Pregnancy and lactation: prescribe only if potential benefit outweighs risk. - Pediatric use: follow age‑specific labeling and monitor growth parameters. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase montelukast plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Phenobarbital: significant reduction in montelukast exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: modest increase in montelukast levels. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Theophylline: possible additive bronchodilator effect; observe for enhanced respiratory response.